These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6105627)

  • 21. A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).
    Poignant JC; Gressier H; Petitjean M; Regnier G; Canevari R
    Experientia; 1975 Oct; 31(10):1204-5. PubMed ID: 1243126
    [No Abstract]   [Full Text] [Related]  

  • 22. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proceedings: Interaction of neuroleptic and cholinergic drugs with central dopaminergic mechanisms.
    Kelly P; Miller RJ; Sahakian B
    Br J Pharmacol; 1974 Nov; 52(3):430P-431P. PubMed ID: 4477511
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of manipulation of cholinergic mechanisms on turning behaviour in mice with unilateral destruction of the nigro-neostriatal dopaminergic system.
    Pycock C; Milson J; Tarsy D; Marsden CD
    Neuropharmacology; 1978 Mar; 17(3):175-83. PubMed ID: 565479
    [No Abstract]   [Full Text] [Related]  

  • 26. Proceedings: Behavioral effects of direct and indirect acting dopaminergic agonists.
    Moore KE
    Psychopharmacol Bull; 1974 Jul; 10(3):41-2. PubMed ID: 4419323
    [No Abstract]   [Full Text] [Related]  

  • 27. Nigral dopaminergic neurons: differential sensitivity to apomorphine following long-term treatment with low and high doses of amphetamine.
    Kamata K; Rebec GV
    Brain Res; 1984 Oct; 321(1):147-50. PubMed ID: 6498510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of drugs altering striatal dopamine levels on apomorphine induced stereotypy.
    Feigenbaum JJ; Yanai J; Blass RB; Moon B; Klawans H
    Pharmacol Biochem Behav; 1982 Feb; 16(2):235-40. PubMed ID: 7200236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apomorphine and amphetamine stereotypy after 6-hydroxydopamine lesions of the substantia nigra.
    Price MT; Fibiger HC
    Eur J Pharmacol; 1974 Dec; 29(2):249-52. PubMed ID: 4613562
    [No Abstract]   [Full Text] [Related]  

  • 30. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

  • 31. [Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
    Pavón N; Vidal L; Alvarez P; Blanco L; Torres A; Rodríguez A; Macías R
    Rev Neurol; 1998 Jun; 26(154):915-8. PubMed ID: 9658459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei.
    Castall B; Marsden CD; Naylor RJ; Pycock CJ
    Brain Res; 1977 Mar; 123(1):89-111. PubMed ID: 300267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones.
    Bunney BS; Aghajanian GK; Roth RH
    Nat New Biol; 1973 Sep; 245(143):123-5. PubMed ID: 4518113
    [No Abstract]   [Full Text] [Related]  

  • 34. The pharmacological and anatomical substrates of the amphetamine response in the rat.
    Creese I; Iversen SD
    Brain Res; 1975 Jan; 83(3):419-36. PubMed ID: 234270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotyped behaviour after cholinergic, but not dopaminergic, stimulation of the substantia nigra in rats.
    Decsi L; Nagy J; Zámbó K
    Life Sci; 1978 Jun; 22(21):1873-8. PubMed ID: 566832
    [No Abstract]   [Full Text] [Related]  

  • 36. On the role of ascending catecholaminergic projections in intracranial self-stimulation of the substantia nigra.
    Clavier RM; Fibiger HC
    Brain Res; 1977 Aug; 131(2):271-86. PubMed ID: 890458
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats.
    Fuller RW; Clemens JA; Kornfeld EC; Snoddy HD; Smalstig EB; Bach NJ
    Life Sci; 1979 Jan; 24(4):375-82. PubMed ID: 34767
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced stereotypes and asymmetric behaviour after substantia nigra pars posterior (SNPP) lesions in cats.
    Wolfarth S; Coelle EF; Osborne NN; Sontag KH; Wand P
    Brain Res; 1979 Dec; 178(2-3):545-54. PubMed ID: 574416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abolition of nomifensine-induced stereotypy after 6-hydroxydopamine lesions of ascending dopaminergic projections.
    Price MT; Fibiger HC
    Pharmacol Biochem Behav; 1976 Aug; 5(2):107-9. PubMed ID: 1033565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.